contraceptive use and uptake
DESCRIPTION
Contraceptive use and uptake. Hasinah Asmal , Samantha Govender, Ian Naicker, Dinesh Singh, Gita Ramjee. BACKGROUND. MDP 301 is a phase III clinical trial testing the efficacy and safety of 0.5% and 2% PRO 2000/5 vaginal microbicides in preventing HIV infection. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/1.jpg)
Contraceptive use and uptake
Hasinah Asmal , Samantha Govender, Ian Naicker, Dinesh Singh,
Gita Ramjee
![Page 2: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/2.jpg)
BACKGROUND
• MDP 301 is a phase III clinical trial testing the efficacy and safety of 0.5% and 2% PRO 2000/5 vaginal microbicides in preventing HIV infection.
• High pregnancy rates continue to pose a challenge impacting on the power of study to show efficacy.
![Page 3: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/3.jpg)
OBJECTIVES
To determine reasons for lack of
contraceptive use among women of
reproductive age.
![Page 4: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/4.jpg)
METHODOLOGY
• Contraception data collected during sexual behaviour interviews was analysed.
• This was a retrospective review of the sexual behaviour interviews of the first 1007 eligible women screened.
![Page 5: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/5.jpg)
Methods of Contraception
![Page 6: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/6.jpg)
![Page 7: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/7.jpg)
RESULTSN = 1007
Eligible women at screening
51 %n = 514
HormonalContraception
49 %n = 493
Not on HormonalContraception
20 %n = 201
NOT on anycontraception
29 %n = 292
Condoms ONLY
REASONS :
See Graph
![Page 8: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/8.jpg)
0
2
4
6
8
10
12
14
16
18
20
Pe
rce
nta
ge
(%
) p
er
Re
as
on
1Reasons Volunteered by Participants
Reasons for Lack of Contraception Use
Side effectsNo ReasonNo ThoughtMenopausePersonal ChoiceOther Misconception about FertilityBreasfeedingInsufficient KnowledgeDefaulted InjectablesMisconception about Age
![Page 9: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/9.jpg)
OTHER included the following :
• Partner opposition• Parental Opposition• Hypertension• Religious reasons• Assumption partner is infertile• Previous pregnancy whilst on contraception
![Page 10: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/10.jpg)
0
51015
202530
354045
% p
artic
ipan
ts r
epo
rtin
g
sid
e ef
fect
sMost Common Side Effects
general(constitutional /systemic)menorrhagia
amenorrhoea
weight gain
watery vaginaldischarge
![Page 11: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/11.jpg)
CONCLUSIONS• 49% of participants are not on hormonal/reliable contraception.• Side effects are a common concern for participants.• A significant percentage of participants provided no reason for lack of
contraception use or admitted to not having given it much thought.• Insufficient family planning education is available to women in our
communities. • HIV prevention trials should invest in family planning issues to ensure safety
of participants and minimal drop outs.• Hormonal contraceptives with low side effect profiles eg. the hormonal patch
and new generation oral contraceptives should be made available.• Quality of care is important in ensuring women make informed decisions that
they will be able to adhere to.• In the first few months after initiation of a new contraceptive method, regular
clinic visits are important as some side effects may appear more severe early on and influence a participant’s decision to discontinue the method.
• Field education visits can increase community awareness of family planning and address common myths.
![Page 12: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/12.jpg)
ACKNOWLEDGEMENTS
Research Participants
Medical Research Council
MDP (Microbicide Development Programme)
DFID (Department for International Development)
![Page 13: Contraceptive use and uptake](https://reader033.vdocuments.site/reader033/viewer/2022061612/56813e15550346895da7f8de/html5/thumbnails/13.jpg)
Contact Information
Hasinah Asmal
HIV Prevention Research Unit
Medical Research Council
Tel. +27 (0)31 242 3600